文献速递前列腺癌

放射性复发高危前列腺癌的临床进展模式

Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
PubMed 文献 · Eur Urol · 2021-05-10

本研究纳入15家机构1997至2015年间978例接受外照射放疗(EBRT,n=654)或EBRT联合近距离放疗(EBRT+BT,n=324)后生化复发的高危前列腺癌患者,评估远处转移(DM)和前列腺癌特异性死亡(PCSM)率。结果显示放射性复发高危前列腺癌自然史侵袭性强,DM在生化复发后早期即可出现,约60%的转移发生在1年内,约30%患者死于前列腺癌。

要点

  • 放射性复发高危前列腺癌侵袭性强,远处转移在生化复发后早期出现。
  • 自复发起算,EBRT和EBRT+BT后5年DM率分别为50%和34%。
  • 自生化复发起算,EBRT和EBRT+BT后5年PCSM率分别为27%和29%。

核心结论

  • 放射性复发高危前列腺癌自然史侵袭性强,远处转移在生化复发后早期即可临床显现。

研究设计与样本

  • 多中心回顾性队列研究,纳入15家机构1997至2015年间978例放射性复发高危前列腺癌患者,其中EBRT 654例(67%),EBRT+BT 324例(33%)。

主要发现

  • 435例发生远处转移,其中248例在生化复发后1年内检出。
  • 自复发起算,EBRT和EBRT+BT后5年DM率分别为50%和34%。
  • 自生化复发起算,EBRT和EBRT+BT后5年PCSM率分别为27%和29%。
  • 至生化复发间隔与DM(p < 0.001)和PCSM(p < 0.001)独立相关。

临床怎么用

  • 对放射性复发高危前列腺癌应重视 upfront 风险评估,复发时及时进行全身系统评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously received either external beam radiation therapy (EBRT, n = 654, 67%) or EBRT + brachytherapy (EBRT + BT, n = 324, 33%) across 15 institutions from 1997 to 2015. In men who did not die, median follow-up after treatment was 8.9 yr and median follow-up after biochemical recurrence (BCR) was 3.7 yr. Local and systemic therapy salvage, respectively, were delivered to 21 and 390 men after EBRT, and eight and 103 men after EBRT + BT. Overall, 435 men developed DM, and 248 were detected within 1 yr of BCR. Measured from time of recurrence, 5-yr DM rates were 50% and 34% after EBRT and EBRT + BT, respectively. Measured from BCR, 5-yr PCSM rates were 27% and 29%, respectively. Interval to BCR was independently associated with DM (p < 0.001) and PCSM (p < 0.001). These data suggest that radiorecurrent HRPCa has an aggressive natural history and that DM is clinically evident early after BCR. These findings underscore the importance of further investigations into upfront risk assessment and prompt systemic evaluation upon recurrence in HRPCa. PATIENT SUMMARY: High-risk prostate cancer that recurs after radiation therapy is an aggressive disease entity and spreads to other parts of the body (metastases). Some 60% of metastases occur within 1 yr. Approximately 30% of these patients die from their prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Philipson RG, Romero T, Wong JK, et al. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol. 2021. PMID: 33985797. doi:10.1016/j.eururo.2021.04.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。